ХРОНИЧЕСКАЯ БОЛЕЗНЬ ПОЧЕК И СОСТОЯНИЕ СЕРДЕЧНО-СОСУДИСТОЙ СИСТЕМЫ

хроническая болезнь почек, сердечно-сосудистый континуум, нейрогуморальный дисбаланс, асимметричный диметиларгинин, гомоцистеин, анемия

1. Ермаков ЮА, Вишняков НИ. Ковальский ГБ. Хроническая почечная недостаточность у нефрологических больных в Санкт-Петербурге по данным патологоанатомических исследований за 1993-2003 годы. Нефрология 2004; 9 (2): 78-82

2. Levey AS, Beto JA, Coronado BE et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 1998; 32 (5): 853-906

3. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998; 9 [Suppl 12]: S16-S23

4. Henry RM, Kostense PJ, Bos G et al. Mild renal insufficiency is associated with increased cardiovascular mortality: the Hoorn Study. Kidney Int 2002; 62 (4): 1402-1407

5. Fried LF, Shlipak MG, Crump C et al. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol 2003; 41 (8): 1364-1372

6. Кузьмин ОБ, Пугаева МО, Чуб СВ. Легкая дисфункция почек у больных с эссенциальной гипертонией: клинические проявления и лекарственная терапия. Нефрология 2004; 8 (3): 15-21

7. O’Riordan E, Foley RN. Effects of anemia on cardiovascular status. Nephrol Dial Transplant 2000; 15 [Suppl 3]: 19-22

8. Goodman WG, London G, Amann K et al. Vascular calcification in chronic kidney disease. Am J Kidney Dis 2004; 43 (3): 372-379

9. Кутырина ИМ, Руденко ТЕ, Дзисоева МЮ. Ремоделрование сосудов при хронической почечной недостаточности. Клин мед 2005; 83 (2): 16-21

10. Смирнов АВ, Добронравов ВА, Каюков ИГ. Кардио-ренальный континуум: патогенетические основы превентивной нефрологии. Нефрология 2005; 9 (3): 7-15

11. Беленков ЮН, Мареев ВЮ. Сердечно-сосудистый континуум. Журн серд недостаточность 2002; 3 (1): 7-11

12. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and risk of death, cardiovascular events and hospitalization. N Engl J Med 2004; 351 (13): 1296-1305

13. Brugts JJ, Knetsch AM, Mattase-Raso FU et al. Renal function and risk of myocardial infarction in elderly population. The Rotterdam study. Arch Intern Med 2005; 165 (22): 2659-2665

14. Rahman M, Pressel S, Davis BR et al. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Intern Med 2006; 144 (3): 172-180

15. Reddan DN, Szczech LA, Tuttle RH et al. Chronic kidney disease, mortality and treatment strategies among patients with significant coronary artery disease. J Am Soc Nephrol 2003; 14 (9): 2373-2380

16. O’Hare AM, Bertenthal D, Shlipak MG et al. Impact of renal insufficiency on mortality in advanced lower extremity peripheral arterial disease. J Am Soc Nephrol 2005; 16 (2): 514-519

17. Vanholder R, Massy Z, Argiles A et al. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005; 20 (6): 1048-1056

18. Berliner JA, Navab M, Fogelman AM et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation and genetics. Circulation 1995; 91 (9): 2488-2496

19. Kaysen GA, Eiserich JP. The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction. J Am Soc Nephrol 2004; 15 (3): 538-548

20. Кутырина ИМ, Руденко ТЕ, Швецов МЮ, Кушнир ВВ. Факторы риска сердечно-сосудистых осложнений у больных на додиализной стадии хронической почечной недостаточности. Тер архив 2006; 78 (5): 45-50

21. Russo D, Palmiero G, De Blasio AP et al. Coronary artery calcification in patients with CRF not undergoing dialysis. Am J Kidney Dis 2004; 44 (6): 1024-1030

22. Tomiyama C, Higa A, Dalboni MA et al. The impact of traditional and non-traditional risk factors on coronary calcification in pre-dialysis patients. Nephrol Dial Transplant 2006; 21 (9): 2464-2471

23. Смирнов АВ, Добронравов ВА, Румянцев АШ, Мнускина ММ. Факторы риска ИБС у больных, получающих лечение гемодиализом. Нефрология 2002; 7 [Прил 1]: 7-13

24. Wang MC, Tsai WC, Chen JY, Huang JJ. Stepwise increase in arterial stiffness corresponding with the stages of chronic kidney disease. Am J Kidney Dis 2005; 45 (3): 494-501

25. Klassen PS, Lowrie EG, Reddan DN et al. Association between pulse pressure and mortality in patients undergoing maintains hemodialysis. JAMA 2002; 287 (12): 1548-1555

26. London GM. Vascular disease and atherosclerosis in uremia. Nefrologia 2005; 25 [Suppl 2]: 91-95

27. Converse RL, Jacobson TN, Toto RD et al. Sympathetic overactivity in patients with chronic renal failure. New Engl J Med 1992; 327 (27): 1912-1918

28. Johansson M, Flam M, Rundquist B et al. Increased sympathetic nerve activity in renovascular hypertension. Circulation1999; 99 (9): 2537-2542

29. Rahman SN, Abraham WT, Van Putten VJ et al. Increased norepinephrine secretion in patients with the nephrotic syndrome and normal glomerular filtration rates: evidence for primary sympathetic activation. Am J Nephrol 1993; 13 (3): 266-270

30. Cerasola G, Vecchi ML, Mule G et al. Sympathetic activity and blood pressure pattern in autosomal dominant polycystic kidney disease hypertensive. Am J Nephrol 1998; 18 (5): 391-398

31. Tinucci T, Abrahao AB, Santello JL, Mion D. Mild chronic insufficiency induces sympathetic overactivity. J Hum Hypertens 2001; 15 (6): 401-406

32. Klein IH, Ligtenberg G, Neumann J et al. Sympathetic nerve activity inappropriately increased in chronic renal disease. J Am Soc Nephrol 2003; 14 (12): 3239-3244

33. Zoccali C, Mallamaci F, Parlengo S et al. Plasma norepinephrine predict survival and incident cardiovascular events in patients with end stage renal disease. Circulation 2002; 105 (11): 1354-1359

34. Adams KF. Pathophysiologic role of renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure. Am J Health Syst Pharm 2004; 61[Suppl 2]: S4-S13

35. Levitan D, Massry SG, Romoff M, Campese VM. Plasma catecholamines and autonomic nervous system function in patients with early renal insufficiency and hypertension. Nephron 1984; 36 (1): 24-29

36. Лифшиц НЛ, Кутырина ИМ. Роль ренин-ангиотензин-альдостероновой системы в патогенезе артериальной гипертонии при хронической почечной недостаточности. Тер архив 1999; 71 (6): 64-67

37. Volpe M, Savoia C, De Paolis P et al. The renin-angiotensin system as a risk factor and therapeutic target for cardiovascular and renal disease. J Am Soc Nephrol 2002; 13 [Suppl 3]: S173-S178

38. Ferrario CM, Strawn WB. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in the cardiovascular disease. Am J Cardiol 2006; 98 (1): 121-128

39. Stier CT, Chander RM, Rocha R et al. Aldosterone as a mediator in cardiovascular injury. Cardiol Rev 2002; 10 (2): 97-107

40. Rossi G, Boscaro M, Ronconi V, Funder JW. Aldosterone as a cardiovascular risk factor. Trends Endocrinol Metab 2005; 16 (3):104-107

41. Shichiri M, Hirata Y, Ando K et al. Plasma endothelin levels in hypertension and chronic renal failure. Hypertension 1990; 15 (5): 493-496

42. Liakopoulus V, Wurth P, Mertens PR et al. Endothelin-1 plasma levels in hemodialysis treatment – the influence of type 2 diabetes.Ren Fail 2005; 27 (5): 515-522

43. Monacsi D, Maqyar J, Tamas B, Nanasi PP. Effect of endothelins on cardiac and vascular cells: new therapeutic target for the future? Curr Vasc Pharmacol 2004; 2 (1): 53-63

44. Van der Harst P, Smilde TD, Buikema H et al. Vascular function and mild renal impairment in stable coronary artery disease. Arterioscler Thromb Vasc Biol 2006; 26 (2): 379-384

45. Teerlink T. ADMA metabolism and clearance. Vasc Med 2005; 10 [Suppl 1]: S73-S81

46. Kielstein JT, Boger JH, Bode-Boger SM et al. Marked increase of asymmetrical dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 2002: 13 (1): 170-176

47. Zoccali C, Benedetto FA, Maas R et al. Asymmetrical dimethylarginine, C-reactive protein and carotid intima-media thickness in end-stage renal disease. J Am Soc Nephrol 2002; 13 (2): 490-496

48. Nanayakkara PW, Teerlink T, Stehouwer CD et al. Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecula-1 (sVCAM) concentration in patients with mild to moderate renal failure. Kidney Int 2005; 68 (5): 2230-2236

49. Zoccali C, Mallamaci F, Maas R et al. Left ventricular hypertrophy, cardiac remodelling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int 2002; 62 (1): 339-345

50. Zoccali C, Bode-Boger S, Mallamaci F et al. Plasma concentration of asymmetric dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358 (9299): 2113-2117

51. Jakubowski H. Pathophysiological consequences of homocysteine excess. J Nutr 2006; [Suppl 6]: S1741-S1749

52. Dayal S, Lentz SR. ADMA and hyperhomocysteinemia. Vasc Med 2005; 10 [Suppl 1]: S27-S33

53. Garibotto G, Sofia A, Valli A et al. Causes of hyperhomocysteinemia in patients with chronic kidney disease. Semin Nephrol 2006; 21 (1): 3-7

54. Смирнов АВ, Добронравов ВА, Голубев РВ и др. Распространенность гипергомоцистеинемии в зависимости от стадии хронической болезни почек. Нефрология 2005; 9 (2): 48-52

55. Menon V, Sarnac MJ, Greene T et al. Relationship between homocysteine and mortality in chronic kidney disease. Circulation 2006; 113 (12): 1572-1577

56. Buccianti G, Baragetti I, Bamonti F et al. Plasma homocysteine levels and cardiovascular mortality in patients with end-stage renal disease. J Nephrol 2004; 17 (3): 405-410 57. Anan F, Takahashi N, Shimomura T et al.

57. Hyperhomocysteinemia is a significant risk factor to silent cerebral infarction in patients with chronic renal failure undergoing hemodialysis. Metabolism 2006; 55 (5): 656-661

58. Abdel-Raheem MM, Hebert B, Potti A et al. Hyperhomocysteinemia and risk of thromboembolic phenomenon in patients with chronic renal disease. Thromb Res 2002; 105 (4): 299-302

59. Astor BC, Muntner P, Levin A et al. Association of kidney function with anemia. Arch Intern Med 2002; 162 (12): 1401-1408

60. McClellan W, Aronoff SL, Bolton WK et al. The prevalence of anaemia in patients with chronic kidney disease. Curr Med Res Opin 2004; 20 (9): 1501-1510

61. Weiner DE, Tighiouart H, Vlagopoulos PT et al. Effect of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease. J Am Soc Nephrol 2005; 16 (6): 1803-1810

62. Astor BC, Coresh J, Heiss G et al. Kidney function and anemia as risk factor for coronary heart disease and mortality: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 2006; 151(2): 492-500

63. Foley RN, Parfrey PS, Harnett JD et al. The impact of anemia on cardiomyopathy, morbidity and mortality in end-stage renal disease.Am J Kidney Dis 1996; 28 (1): 53-61

64. Li S, Foley RN, Collins AJ. Anemia, hospitalization and mortality in patients receiving peritoneal dialysis in the United States. Kidney Int 2004; 65 (5): 1864-1869

65. Solomon SD, Rice MM, Jablonski K et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation 2006; 114 (1): 26-31

66. Nakamura T, Kanno Y, Takenaka T et al. Angiotensin receptor blockers reduces the risk of congestive heart failure in elderly hypertensive patients with renal insufficiency. Hypertens Res 2005; 28 (5): 415-423

67. Takanashi A, Takase H, Toriyama T et al. Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic hemodialysis – a randomized study. Nephrol Dial Transplant 2006; 21 (9): 2507-2512

68. Abbot KC, Trespalacios FC, Agodoa CY et al. в-Blocker use in long-term dialysis patients. Arch Intern Med 2004; 164 (22): 2465-2471

69. Nakayama M, Ishii A, Takequchi F, Nakano H. Efficacy of additional low-dose carvedolol in maintenance hemodialysis patients with asymptomatic left ventricular systolic dysfunction. J Cardiol 2006; 47 (6): 285-291

70. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 2006; 17 (7): 2006-2016

71. Kidney Disease Outcomes Quality Initiative Group. K/DOQI guidelines for management of dyslipidemias in patients with chronic renal disease. Am J Kidney Dis 2003; 41 [Suppl]: S1-S91

72. Wanner C, Krane V, Mars W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.N Engl J Med2005; 353 (3): 238-248